Download Sample
Add to CartGlobal Viscosupplementation Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Dosage;
Single Injection, Three Injection, and Five InjectionBy Arthritis Type;
Osteoarthritis and Rheumatoid ArthritisBy Application;
Knee Osteoarthritis, Hip Osteoarthritis, Shoulder Osteoarthritis, and OthersBy End User;
Hospitals, Ambulatory Surgical Centers, and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Global Viscosupplementation Market Overview
Global Viscosupplementation Market (USD Million)
Viscosupplementation Market was valued at USD 3,936.51 million in the year 2024. The size of this market is expected to increase to USD 6,999.72 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.6%.
Global Viscosupplementation Market Growth, Share, Size, Trends and Forecast
*Market size in USD million
CAGR 8.6 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 8.6 % |
| Market Size (2024) | USD 3,936.51 Million |
| Market Size (2031) | USD 6,999.72 Million |
| Market Concentration | Medium |
| Report Pages | 390 |
Major Players
- Fidia Farmaceutici s.p.a
- Ferring Pharmaceuticals
- Anika Therapeutics Inc
- Bioventus LLC
- Sanofi SA
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Global Viscosupplementation Market
Fragmented - Highly competitive market without dominant players
The viscosupplementation market is expanding as more individuals seek effective solutions for joint degeneration without resorting to surgery. As osteoarthritis becomes more common due to aging and lifestyle factors, over 55% of affected individuals are turning to viscosupplements for relief. These injections are favored for their ability to ease joint pain and improve mobility with minimal procedural risk.
Dominance of Hyaluronic Acid-Based Formulations
A significant portion of the market is driven by hyaluronic acid-based injections, known for enhancing joint lubrication and reducing inflammation. These options account for nearly 60% of viscosupplementation treatments, reflecting their strong therapeutic profile and widespread acceptance in clinical practice. Their compatibility with early-stage management has further encouraged adoption.
Product Advancements Driving Market Appeal
Innovations in viscosupplementation delivery systems, such as single-dose and multi-dose options, are helping tailor treatment to individual needs. More than 30% of recent product developments emphasize ease of use and improved outcomes, making them attractive to healthcare providers and patients alike. These advancements are elevating both treatment efficiency and user experience.
Preventive Joint Care Influencing Market Growth
With awareness campaigns highlighting the importance of early orthopedic intervention, more patients are proactively seeking viscosupplementation. Currently, about 45% of individuals experiencing joint discomfort are opting for these treatments as a preventive measure. This shift toward early action is fostering steady growth in the market.
Viscosupplementation Market Recent Developments
-
In April 2018, Bone Therapeutics S.A. finished clinical studies for its JTA-004 intra-articular injection for knee OA.
-
In April 2022, Juniper Biologics licensed TissueGene-C low dose (TG-C LD), a non-surgical treatment for knee osteoarthritis, to Kolon Life Sciences for development and commercialization. According to the licensing agreement, Juniper will develop and commercialize gene therapy to medical professionals and hospitals in Asia-Pacific, the Middle East, and Africa.
Viscosupplementation Market Segment Analysis
In this report, the Viscosupplementation Market has been segmented by Dosage, Arthritis Type, Application, End User and Geography.
Viscosupplementation Market, Segmentation by Dosage
The Viscosupplementation Market has been segmented by Dosage into Single Injection, Three Injection and Five Injection.
Single Injection
Single Injection treatments dominate the viscosupplementation market, contributing approximately 52% of global revenue in 2022. This segment is driven by the growing preference for convenience and reduced procedural frequency. The ability to provide effective symptom relief with fewer injections appeals to both patients and healthcare providers.
Three Injection
Three Injection treatments account for around 34% of the global viscosupplementation market. This regimen provides a balance between treatment efficacy and cost-effectiveness, making it a popular option for moderate osteoarthritis cases. The established clinical benefits of three-injection series support ongoing demand.
Five Injection
Five Injection treatments hold an estimated 14% share of the global viscosupplementation market. This regimen is typically used in severe cases requiring enhanced symptom management over an extended period. The availability of high-molecular-weight hyaluronic acid products supports the effectiveness of this segment.
Viscosupplementation Market, Segmentation by Arthritis Type
The Viscosupplementation Market has been segmented by Arthritis Type into Osteoarthritis, and Rheumatoid Arthritis.
Osteoarthritis
Osteoarthritis holds the largest share of the viscosupplementation market, contributing approximately 85% of global revenue in 2022. The high prevalence of osteoarthritis globally, especially among the aging population, drives strong demand. Viscosupplementation treatments are widely used to manage symptoms and improve joint mobility in patients with knee and hip osteoarthritis.
Rheumatoid Arthritis
Rheumatoid Arthritis accounts for around 15% of the global viscosupplementation market. Although viscosupplementation is less commonly used for rheumatoid arthritis compared to osteoarthritis, its application in certain cases to reduce joint pain and improve mobility is gaining attention. Combination therapies and individualized treatment plans contribute to market demand in this segment.
Viscosupplementation Market, Segmentation by Application
The Viscosupplementation Market has been segmented by Application into Knee Osteoarthritis, Hip Osteoarthritis, Shoulder Osteoarthritis and Others.
Knee Osteoarthritis
Knee Osteoarthritis dominates the viscosupplementation market, contributing approximately 72% of global revenue in 2022. This dominance is driven by the high prevalence of knee osteoarthritis, particularly among elderly patients. Viscosupplementation therapies are widely used to relieve joint pain, improve mobility, and delay joint replacement surgeries.
Hip Osteoarthritis
Hip Osteoarthritis accounts for around 14% of the global viscosupplementation market. The application of viscosupplementation in hip joints is growing, offering relief from pain and improving quality of life for patients with moderate to severe symptoms. Increased awareness and improved access to advanced treatment options support this segment’s growth.
Shoulder Osteoarthritis
Shoulder Osteoarthritis holds an estimated 8% share of the global viscosupplementation market. Although less common than knee or hip osteoarthritis, viscosupplementation treatments provide an effective option for pain management and mobility improvement in patients with shoulder joint issues. This segment is expected to grow as clinical evidence supporting its efficacy expands.
Others
The "Others" category, which includes ankle and temporomandibular joint osteoarthritis, contributes around 6% of the global viscosupplementation market. Although relatively small, this segment addresses specialized treatment needs and supports the market’s diversification across various joint types.
Viscosupplementation Market, Segmentation by End User
The Viscosupplementation Market has been segmented by End User into Hospitals, Ambulatory Surgical Centers, and Others.
Hospitals
Hospitals dominate the viscosupplementation market, contributing approximately 60% of global revenue in 2022. These facilities offer comprehensive diagnostic and treatment services for osteoarthritis and related conditions, supported by the availability of specialized equipment and skilled healthcare professionals. The rising volume of inpatient procedures drives sustained demand in this segment.
Ambulatory Surgical Centers
Ambulatory Surgical Centers (ASCs) account for around 25% of the global viscosupplementation market. ASCs offer cost-effective and efficient care for patients requiring single-injection or multi-injection therapies. Their ability to provide outpatient treatments with shorter recovery times supports increasing adoption in this segment.
Others
The "Others" category, including physician offices, specialty clinics, and home care settings, holds an estimated 15% share of the global viscosupplementation market. These settings cater to patients seeking personalized care and offer flexibility in treatment administration. Growing awareness of non-hospital-based care options supports market expansion.
Viscosupplementation Market, Segmentation by Geography
In this report, the Viscosupplementation Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Regions and Countries Analyzed in this Report
Viscosupplementation Market Share (%), by Geographical Region
North America
North America leads the viscosupplementation market, accounting for approximately 41% of global revenue in 2022. The region's dominance is driven by high prevalence of osteoarthritis, advanced healthcare infrastructure, and strong presence of key market players. Increasing awareness and availability of advanced viscosupplementation treatments further fuel growth.
Europe
Europe holds around 29% of the global viscosupplementation market. The region benefits from rising demand for minimally invasive therapies, expanding geriatric population, and supportive healthcare policies. Growing emphasis on early diagnosis and treatment of osteoarthritis drives this segment.
Asia Pacific
Asia Pacific accounts for an estimated 19% share of the global viscosupplementation market. Rapidly improving healthcare infrastructure, increasing chronic disease prevalence, and rising awareness of advanced treatments fuel growth in this region. Countries such as China, India, and Japan contribute significantly due to expanding aging populations and rising healthcare investments.
Middle East and Africa
Middle East and Africa contribute approximately 6% of the global viscosupplementation market. Growth is supported by expanding healthcare access, rising government investments in healthcare technology, and growing demand for non-surgical treatment options. Partnerships with global market leaders further enhance market development.
Latin America
Latin America holds around 5% of the global viscosupplementation market. Growth drivers include rising osteoarthritis prevalence, increasing healthcare investments, and improving access to advanced viscosupplementation therapies. Efforts to strengthen healthcare systems and expand minimally invasive treatment options contribute to growth.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Viscosupplementation Market. These factors include; Market Drivers, Restraints and Opportunities.
Drivers, Restraints and Opportunity Analysis
Drivers
- Aging Population
- Advancements in Viscosupplement Formulations
-
Increasing Preference for Minimally Invasive Treatment Options - One key driver behind the increasing preference for minimally invasive treatment options, including viscosupplementation, is the desire to avoid or delay more invasive surgical procedures, such as joint replacement surgery. Osteoarthritis, the primary indication for viscosupplementation, is a chronic degenerative joint disease characterized by joint pain, stiffness, and functional impairment. While joint replacement surgery remains a viable treatment option for severe cases of osteoarthritis, many patients and healthcare providers seek less invasive alternatives to preserve joint function, minimize post-operative complications, and avoid the risks associated with major surgery.
The aging population and the prevalence of osteoarthritis contribute to the growing demand for minimally invasive treatments that address the unique needs and preferences of older adults. With increasing life expectancy and active lifestyles, individuals are seeking non-surgical interventions that allow them to maintain mobility, independence, and overall quality of life. Viscosupplementation offers a conservative approach to managing osteoarthritis symptoms, providing pain relief, improving joint function, and delaying the progression of joint degeneration, thereby meeting the evolving healthcare needs of an aging population.
Advancements in viscosupplement formulations, injection techniques, and imaging technologies have enhanced the safety, efficacy, and precision of minimally invasive procedures, further driving their popularity among patients and healthcare providers. Newer viscosupplementation products offer improved viscosity, durability, and tissue penetration, allowing for more targeted delivery and longer-lasting symptom relief. Advanced imaging modalities, such as ultrasound and fluoroscopy, enable accurate intra-articular injections, ensuring optimal placement of viscosupplements and maximizing treatment outcomes.
Restraints
- Limited Reimbursement Coverage
- Potential Adverse Events
-
High Cost of Viscosupplement Products - The high cost of viscosupplement products poses financial challenges for patients, particularly those without adequate insurance coverage or access to reimbursement programs. For individuals with osteoarthritis seeking relief from joint pain and stiffness, the out-of-pocket expenses associated with viscosupplementation injections can be prohibitive, leading to treatment barriers and delays in seeking care. Moreover, the cost burden of viscosupplements may exacerbate socioeconomic disparities in healthcare access, disproportionately affecting vulnerable populations and underserved communities with limited financial resources.
Healthcare systems and payers also face challenges in managing the escalating costs of viscosupplementation therapies within budget constraints. The high unit cost of viscosupplement products strains healthcare budgets, reimbursement models, and formulary decisions, prompting payers to impose restrictions, coverage limitations, or utilization management strategies to control expenditures. This may result in reimbursement denials, prior authorization requirements, or step therapy protocols that impede patient access to viscosupplementation treatments, despite their clinical benefits and efficacy in osteoarthritis management.
The high cost of viscosupplement products presents economic considerations for healthcare providers and facilities, impacting practice economics, revenue streams, and resource allocation decisions. Orthopedic practices, hospitals, and ambulatory surgical centers may face financial pressures in procuring viscosupplements, managing inventory, and balancing treatment costs with reimbursement rates and patient demand. The financial implications of viscosupplementation may influence treatment decisions, treatment modalities, and patient counseling, as healthcare providers navigate the complex landscape of healthcare financing and delivery.
Opportunities
- Expansion of Indications for Viscosupplementation
- Emerging Markets and Untapped Patient Populations
-
Development of Next-Generation Viscosupplements - One key opportunity lies in the advancement of viscosupplement formulations with improved viscoelastic properties and rheological characteristics. Next-generation viscosupplements may incorporate modifications such as cross-linking, hybrid formulations, or combination therapies to enhance joint lubrication, reduce friction, and provide prolonged pain relief. By optimizing the molecular structure and biomechanical properties of hyaluronic acid, these formulations offer enhanced tissue penetration, joint residence time, and therapeutic efficacy, leading to improved symptom management and functional outcomes for patients with osteoarthritis.
The development of next-generation viscosupplements encompasses novel delivery systems and administration techniques aimed at improving treatment convenience, patient compliance, and intra-articular targeting. This includes advancements such as extended-release formulations, intra-articular depots, and smart injection devices designed to optimize drug delivery kinetics, minimize treatment frequency, and enhance drug localization within the joint space. By facilitating sustained drug release and intra-articular retention, these delivery systems offer potential benefits in reducing treatment burden, improving patient adherence, and maximizing therapeutic effects over time.
Next-generation viscosupplements present opportunities for personalized and precision medicine approaches in osteoarthritis management. Advanced technologies such as biomarker-guided therapy, genetic profiling, and tissue engineering may enable tailored treatment regimens and patient-specific interventions based on individual disease characteristics, joint biomechanics, and treatment response. By integrating patient-centric approaches and predictive analytics into viscosupplementation strategies, healthcare providers can optimize treatment outcomes, minimize adverse events, and optimize resource allocation in osteoarthritis care.
Competitive Landscape Analysis
Key players in Global Viscosupplementation Market include:
- Fidia Farmaceutici spa
- Ferring Pharmaceuticals
- Anika Therapeutics Inc
- Bioventus LLC
- Sanofi SA
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Dosage
- Market Snapshot, By Arthritis Type
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Viscosupplementation Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Aging Population
-
Advancements in Viscosupplement Formulations
-
Increasing Preference for Minimally Invasive Treatment Options
-
- Restraints
-
Limited Reimbursement Coverage
-
Potential Adverse Events
-
High Cost of Viscosupplement Products
-
- Opportunities
-
Expansion of Indications for Viscosupplementation
-
Emerging Markets and Untapped Patient Populations
-
Development of Next-Generation Viscosupplements
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Viscosupplementation Market, By Dosage, 2021 - 2031 (USD Million)
-
Single Injection
-
Three Injection
-
Five Injection
-
- Viscosupplementation Market, By Arthritis Type, 2021 - 2031 (USD Million)
- Osteoarthritis
- Rheumatoid Arthritis
- Viscosupplementation Market, By Application, 2021 - 2031 (USD Million)
- Knee Osteoarthritis
- Hip Osteoarthritis
- Shoulder Osteoarthritis
- Others
- Viscosupplementation Market, By End User, 2021 - 2031 (USD Million)
-
Hospitals
-
Ambulatory Surgical Centers
-
Others
-
- Viscosupplementation Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Viscosupplementation Market, By Dosage, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Fidia Farmaceutici s.p.a
- Ferring Pharmaceuticals
- Anika Therapeutics Inc
- Bioventus LLC
- Sanofi SA
- Company Profiles
- Analyst Views
- Future Outlook of the Market